Jina Kim
Family Medicine · Duluth, GANPI 1114155702
Payments from drug & device makers
Across 1,256 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$3K
- Amarin Pharma, Inc.$2K
- Pfizer$1K
- AstraZeneca$1K
- Sanofi-aventis U.S. LLC$1K
- plus $10K from 51 others
What the payments were for
- Food & beverage$20,87799%
- Education$1791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,056 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 159 | $186,516 |
| ProliaDenosumab | 107 | $184,134 |
| VascepaIcosapent Ethyl | 191 | $161,484 |
| CreonLipase/Protease/Amylase | 60 | $118,530 |
| ForteoTeriparatide | 18 | $74,271 |
| ZenpepLipase/Protease/Amylase | 17 | $58,600 |
| OzempicSemaglutide | 31 | $56,022 |
| JardianceEmpagliflozin | 37 | $55,734 |
| TradjentaLinagliptin | 46 | $46,187 |
| Repatha SureclickEvolocumab | 33 | $30,156 |
| JanuviaSitagliptin Phosphate | 25 | $26,145 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $26,102 |
| EliquisApixaban | 20 | $25,764 |
| NamzaricMemantine Hcl/Donepezil Hcl | 17 | $22,837 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $17,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,068 | $186,516159 claims |
| AmgenProlia | $2,747 | $184,134107 claims |
| AbbVieCreon, Namzaric, Linzess | $2,809 | $157,31694 claims |
| Boehringer IngelheimJardiance, Tradjenta | $329 | $101,92183 claims |
| Lilly USA, LLCForteo | $878 | $74,27118 claims |
| Aimmune Therapeutics, Inc.Zenpep | $132 | $58,60017 claims |
| Novo NordiskOzempic | $925 | $56,02231 claims |
| MerckJanuvia, Janumet Xr | $370 | $44,00740 claims |
| PfizerEliquis | $1,381 | $25,76420 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,020 | $17,99311 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $225 | $15,91611 claims |
| Johnson & JohnsonXarelto | $358 | $14,41912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Duluth
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.